None listed
Conditions
Brief summary
The aim of this study is to assess the effects of sitting compared with lying on lower limb venous blood flow and to assess whether the ErgoCentric seat results in a lesser reduction in lower limb venous blood flow than the Herman Miller Aeron chair (an office seat available internationally).
Interventions
Venous blood flow will be measured after subjects have lain prone for 5 minutes (baseline; time (T) = 5). They will then be randomly allocated to sit first in either the intervention chair (the ergoCentric ergonomic chair) or the control chair. Venous blood flow will be measured again after subjects have sat in the ergoCentric ergonomic chair with their legs at a 90 degree angle for 5 minutes and then when they have sat with their legs at a 120 degree angle for 5 minutes. (T = 10 and T =15 resp
Venous blood flow will be measured after subjects have lain prone for 5 minutes (baseline; time (T) = 5). They will then be randomly allocated to sit first in either the intervention chair (the ergoCentric ergonomic chair) or the control chair. Venous blood flow will be measured again after subjects have sat in the ergoCentric ergonomic chair with their legs at a 90 degree angle for 5 minutes and then when they have sat with their legs at a 120 degree angle for 5 minutes. (T = 10 and T =15 respectively). The total time subjects will spend seated in the ergoCentric ergonomic chair will be 10 minutes. The subjects will then lie prone for 5 minutes to re-establish the baseline blood flow rate which will be measured at T=20 and they will then cross over to the control treatment (i.e. there will be a 5 minute period during which time subjects will lie prone before they crossover to the control). Blood flow measurement is not continuous but will occur after the subject has spent 5 minutes in each posture.
Sponsors
ErgoCentric Seating Systems
Study design
Allocation
Randomised controlled trial
Intervention model
Crossover
Primary purpose
Prevention
Masking
Open (masking not used)
Eligibility
Sex/Gender
All
Age
18 Years to No maximum
Healthy volunteers
Yes
Inclusion criteria
Generally healthy adult volunteers with no known vascular history considered significant by the investigator; able to give informed consent.
Exclusion criteria
Unable or unwilling to give informed consent; vascular history considered significant by the investigator; unable to comply with the study requirements; Under 18 years in age.
Outcome results
None listed